Recombinant ITGA4 (Natalizumab Biosimilar) anticorps

N° du produit ABIN5668196

Cet anticorps Human Monoclonal détecte spécifiquement ITGA4 (Natalizumab Biosimilar) dans FACS et BR. Il présente une réactivité envers Humain et a été mentionné dans 1 publication.

Aperçu rapide pour Recombinant ITGA4 (Natalizumab Biosimilar) anticorps (ABIN5668196)

Antigène: ITGA4 (Natalizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp ITGA4 (Natalizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), Blocking Reagent (BR)

Détail du produit anti-ITGA4 (Natalizumab Biosimilar) anticorps

Fonction: Anti-Integrin alpha 4 [Natalizumab], Human IgG4, kappa

Specificité: This antibody binds to the alpha 4 binds subunit of α4β1 (also known as very late antigen 4 [VLA-4] or CD49d-CD29) and α4β7 integrin

Attributs du produit:

Original Species of Ab: Human

Original Format of Ab: IgG4

Purification: Protein A affinity purified

Pureté: > 98 % as determined by SDS-PAGE

niveau d'endotoxine: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogène: The RAMOS cell line, a non-EBV releasing cell line, injected into mice.

Isotype: IgG4 kappa

Information d'application

Indications d'application: This antibody binds to human integrin alpha 4 and has been used to treat Multiple Sclerosis and Crohn's Disease.

Commentaires:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Références pour anticorps anti-ITGA4 (Natalizumab Biosimilar) (ABIN5668196)

Cegarra, Cameron, Chaves, Dabdoubi, Do, Genêt, Roudières, Shi, Tchepikoff, Lesuisse: "An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family." dans: PloS one, Vol. 17, Issue 9, pp. e0274667, (2022) (PubMed).

Détails sur ITGA4 (Natalizumab Biosimilar)

Antigène: ITGA4 (Natalizumab Biosimilar)

Sujet: CD49D, alpha 4 subunit of VLA-4 receptor, ITGA4, Integrin alpha-IV

UniProt: P13612